Skip to content
value.today

Genenews Ltd.

Formerly ChondroGene Limited, Lewis Brook Resources Ltd.

Total raised
$25 M
7 rounds on record
Latest round
$1 M
Mar 2022
First round on record
Nov 2010
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Genenews Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2022$1 MNo. 7Under $2 million

Genenews Ltd.: Raise no. 7, Mar 2022

Investors in this round

1 investor had bought by the notice of Mar 17, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $3 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Each unit consists of one common share and one transferable share purchase warrant. Each whole warrant is exercisable for one additional share until March 2, 2026 at Cdn$0.2206 per share.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
$5 million to $25 million
Sales commissions
$227,882
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Ontario, Canada

People named in the notice

  • James R. Howard-Tripp · Executive Officer, Director
  • Garth R. MacRae · Director
  • Harry R. Glorikian · Director
  • Richard Janice Huston · Director
  • Rory Janice Riggs · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “Includes broker warrants to purchase 800,000 common shares of the issuer at Cdn$0.2206 per share for a period of 4 years.”
  • On the amounts: “The additional $1,741,396.00 may be received upon the exercise of share purchase warrants sold inside or outside the U.S. Dollar amounts are based on the Bank of Canada average rate of exchange reported on March 2, 2022, which wad Cdn$1.2668=USD$1.00.”
  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”

Signed by Matthew Peitras, Cfo & coo. Source: SEC Form D, newest notice filed Mar 17, 2022. Read the notice at the SEC.

equity, optionsSEC
Nov 2021$3 MNo. 6$2 to $10 million

Genenews Ltd.: Raise no. 6, Nov 2021

Investors in this round

6 investors had bought by the notice of Feb 7, 2022: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $7 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Each unit consists of one common share and one transferable share purchase warrant. Each whole warrant is exercisable for one additional share until November 25, 2025 at Cdn$0.56 per share.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
$1 million to $5 million
Sales commissions
$524,960
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Ontario, Canada

People named in the notice

  • James R. Howard-Tripp · Executive Officer, Director
  • Garth R. MacRae · Director
  • Harry R. Glorikian · Director
  • Richard Janice Huston · Director
  • Rory Janice Riggs · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NY, TX

Remarks in the notice

  • On fees: “Includes broker warrants to purchase750,000 common shares of the issuer at Cdn$0.56 per share for a period of 4 years.”
  • On the amounts: “The additional $4,110,877.00 may be received upon the exercise of share purchase warrants sold inside or outside the U.S. Dollar amounts are based on the Bank of Canada average rate of exchange reported on November 26, 2021, which wad Cdn$1.2771=USD$1.00.”
  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”

Signed by James Howard-Tripp, Chairman and CEO. Source: SEC Form D and 1 amendment, newest notice filed Feb 7, 2022. Read the notice at the SEC.

equity, optionsSEC
Jun 2018$2 MNo. 5Under $2 million

Genenews Ltd.: Raise no. 5, Jun 2018

Investors in this round

1 investor had bought by the notice of Jun 22, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Each warrant is exercisable for one common share at an exercise price of CDN$0.096 for a period of 36 months. The convertible note has a 30 month term and bears interest of 8% per annum.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Ontario, Canada

People named in the notice

  • James Howard-Tripp · Executive Officer, Director
  • Leslie Auld · Executive Officer, Director
  • Garth MacRae · Director
  • Harry Glorikian · Director
  • Rory Riggs · Director
  • Thomas Stewart Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The additional $1,001,429.00 may be received upon the exercise of share purchase warrants sold inside and outside the U.S. U.S. dollar amounts are based on the Bank of Canada average rate of exchange reported on June 7, 2018, which was CDN$1.2972=US$1.00.”
  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”

Signed by James Howard-Tripp, Ceo. Source: SEC Form D, newest notice filed Jun 22, 2018. Read the notice at the SEC.

equity, debt, optionsSEC
Jul 2014$6 MNo. 4$2 to $10 million

Genenews Ltd.: Raise no. 4, Jul 2014

Investors in this round

8 investors had bought by the notice of Jul 22, 2014: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $7 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Ontario, Canada

People named in the notice

  • James C. Howard-Tripp · Executive Officer, Director
  • Leslie Auld · Executive Officer, Director
  • Floyd C. Dent III · Director
  • Garth C. MacRae · Director
  • Harry C. Glorikian · Director
  • Heiner Dreismann · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Leslie Auld, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 22, 2014. Read the notice at the SEC.

equitySEC
Dec 2012$6 MNo. 3$2 to $10 million

Genenews Ltd.: Raise no. 3, Dec 2012

Investors in this round

14 investors had bought by the notice of Dec 28, 2012: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Ontario, Canada

People named in the notice

  • Gailina Liew · Executive Officer, Director
  • Heiner Dreismann · Executive Officer, Director
  • Karl Wassmann · Executive Officer
  • Leslie Auld · Executive Officer
  • David Sable · Director
  • Garth MacRae · Director
  • Harry Glorikian · Director
  • James Howard-Tripp · Director
  • Rory Riggs · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Sales were made to U.S. purchasers in 3 tranches on December 14, 17 & 18, 2012. The applicable noon exchange rate, as issued by the Bank of Canada, was used to calculate the aggregate total offering amount on each date of the respective tranches.”

Signed by Leslie Auld, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 28, 2012. Read the notice at the SEC.

equitySEC
Jun 2011$5 MNo. 2$2 to $10 million

Genenews Ltd.: Raise no. 2, Jun 2011

Investors in this round

11 investors had bought by the notice of Jun 23, 2011: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Ontario, Canada

People named in the notice

  • Gailina A Liew · Executive Officer, Director
  • Heiner Dreismann · Executive Officer, Director
  • Leslie A Auld · Executive Officer
  • David A Sable · Director
  • Garth MacRae · Director
  • Harry A Glorikian · Director
  • James Howard-Tripp · Director
  • Rory Riggs · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Working capital, expanding access to the ColonSentry(TM) test in Canada, the United States, Europe and Asia, and pipeline development.”

Signed by Gailina Liew, Chief Operating Officer. Source: SEC Form D, newest notice filed Jun 23, 2011. Read the notice at the SEC.

equity, optionsSEC
Nov 2010$1 MNo. 1Under $2 million

Genenews Ltd.: Raise no. 1, Nov 2010

Investors in this round

7 investors had bought by the notice of Nov 26, 2010: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Ontario, Canada

People named in the notice

  • Gailina A Liew · Executive Officer, Director
  • Heiner Dreismann · Executive Officer, Director
  • Leslie A Auld · Executive Officer
  • David A Sable · Director
  • Garth MacRae · Director
  • Harry A Glorikian · Director
  • James Howard-Tripp · Director
  • Rory Riggs · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “General working capital purposes, the continued marketing of the ColonSentry test in Canada and the pre-launch preparation for the commercial launch of the ColonSentry test into the United States and Asia.”

Signed by Leslie Auld, Chief Financial Officer and Treasurer. Source: SEC Form D, newest notice filed Nov 26, 2010. Read the notice at the SEC.

equity, debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Genenews Ltd. had revenue between $5 million and $25 million when it filed its newest notice of a funding round (Mar 2022).

    SEC Form D (revenue range) · Mar 2022

  • Revenue range over time, as stated in its notices: revenue of up to $1 million in 2010; revenue of up to $1 million in 2011; revenue of up to $1 million in 2018; revenue between $5 million and $25 million in 2022.

    SEC Form D (revenue range) · Mar 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2022

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Genenews Ltd. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 14 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Genenews Ltd.
NameRoleNamed in
James R. Howard-TrippExecutive officerMar 2022
James Howard-TrippExecutive officerJun 2018
Leslie AuldExecutive officerJun 2018
James C. Howard-TrippExecutive officerJul 2014
Gailina LiewExecutive officerDec 2012
Heiner DreismannExecutive officerDec 2012
Karl WassmannExecutive officerDec 2012
Gailina A LiewExecutive officerJun 2011
Leslie A AuldExecutive officerJun 2011
Garth R. MacRaeDirectorMar 2022
Harry R. GlorikianDirectorMar 2022
James R. Howard-TrippDirectorMar 2022
Richard Janice HustonDirectorMar 2022
Rory Janice RiggsDirectorMar 2022
Garth MacRaeDirectorJun 2018
Harry GlorikianDirectorJun 2018
James Howard-TrippDirectorJun 2018
Leslie AuldDirectorJun 2018
Rory RiggsDirectorJun 2018
Thomas Stewart Jr.DirectorJun 2018
Floyd C. Dent IIIDirectorJul 2014
Garth C. MacRaeDirectorJul 2014
Harry C. GlorikianDirectorJul 2014
Heiner DreismannDirectorJul 2014
James C. Howard-TrippDirectorJul 2014
David SableDirectorDec 2012
Gailina LiewDirectorDec 2012
David A SableDirectorJun 2011
Gailina A LiewDirectorJun 2011
Harry A GlorikianDirectorJun 2011